Anavex Confirms Phase 2a Trial Data of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC

Anavex Life Sciences Corp.

confirmed positive results from the Phase 2a Alzheimer's study for ANAVEX 2-73. Two days back, it released the statement on the update about the trial. Following this, the stock advanced more than ten percent. Anavex advisor and an Alzheimer clinical trialist, Norman Relkin, said: "To interpret the ANAVEX 2-73 results presented at the 2016 AAIC meeting, it is important to keep in mind the stated goals of this first in Alzheimer's patients study. This was a Phase 2a study, primarily designed to determine which ANAVEX 2-73 dosages are safe to administer to mild to moderate stage Alzheimer's patients." The company indicated that the trial was successful in establishing the maximum tolerated dose apart from revealing the range of ANAVEX 2-73 doses, which were well-tolerated by Alzheimer patients. The study also offered encouraging evidence confirming the previously reported positive trends in some cognitive and biologic measures persisted over a period of approximately 31 weeks. However, the company clarified that this analysis was based on a relatively small number of subjects receiving a variety of doses. Therefore, the company said that that these findings might not reflect the full potential ANAVEX 2-73 in treating Alzheimer's disease. Anavex indicated that a detailed pre-planned analysis of the pharmacodynamic results is in progress. The company believes that it is one of the key factors of relevance for regulatory agencies to assess the maximum dose for future studies. At the time of writing this, shares of the company traded $0.41 or 11.75 percent at $3.92 on Friday.